SLC5A2 and stroke disorder: This meta-analysis of the data derived from five RCTs involving 46,969 participants showed that treatment with SGLT2 inhibitors did not increase the risk of total stroke events and there was a neutral effect among different stroke subtypes apart from hemorrhagic stroke.